Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Geron Corp (GERN)

Geron Corp (GERN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 517,102
  • Shares Outstanding, K 377,447
  • Annual Sales, $ 1,390 K
  • Annual Income, $ -116,110 K
  • 60-Month Beta 0.99
  • Price/Sales 368.51
  • Price/Cash Flow N/A
  • Price/Book 4.52
Trade GERN with:

Options Overview Details

View History
  • Implied Volatility 103.88% ( -36.28%)
  • Historical Volatility 60.84%
  • IV Percentile 79%
  • IV Rank 33.61%
  • IV High 305.16% on 02/22/22
  • IV Low 1.96% on 04/12/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 872
  • Volume Avg (30-Day) 1,505
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 113,263
  • Open Int (30-Day) 101,046

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.09
  • Number of Estimates 3
  • High Estimate -0.09
  • Low Estimate -0.09
  • Prior Year -0.09
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1800 +16.10%
on 06/16/22
1.4900 -8.05%
on 06/09/22
+0.1000 (+7.87%)
since 05/24/22
3-Month
1.1700 +17.09%
on 03/28/22
1.6800 -18.45%
on 04/07/22
+0.1300 (+10.48%)
since 03/24/22
52-Week
0.9899 +38.40%
on 02/03/22
1.7400 -21.26%
on 11/09/21
-0.1500 (-9.87%)
since 06/24/21

Most Recent Stories

More News
Radius (RDUS) to Go Private With $890M Deal, Shares Gain

Radius (RDUS) will go private following the acquisition by Gurnet Point Capital and Patient Square Capital.

GERN : 1.3700 (+0.74%)
LLY : 325.62 (+4.13%)
AMGN : 245.37 (+0.94%)
RDUS : 10.11 (-6.73%)
Gilead (GILD) Announces Positive Data on Hepcludex for HDV

Gilead (GILD) Hepcludex meets the primary endpoint in a phase III study for the treatment of chronic hepatitis delta virus (HDV) infection at 48 weeks.

GSK : 43.69 (+2.20%)
GERN : 1.3700 (+0.74%)
ALKS : 29.71 (+0.51%)
GILD : 63.08 (+0.80%)
Radius (RDUS), Menarini Submit NDA for Breast Cancer Drug

Radius (RDUS) and partner The Menarini Group submit a new drug application to the FDA for elacestrant for treating patients with ER+/HER2- advanced or metastatic breast cancer.

GERN : 1.3700 (+0.74%)
LLY : 325.62 (+4.13%)
AMGN : 245.37 (+0.94%)
RDUS : 10.11 (-6.73%)
Novartis' (NVS) Oncology Drugs Get Approval for Label Expansion

Novartis (NVS) obtains regulatory approval for label expansion of Tafinlar + Mekinist and Tabrecta.

NVS : 84.83 (+3.63%)
GERN : 1.3700 (+0.74%)
ALKS : 29.71 (+0.51%)
INCY : 78.19 (+4.56%)
Exelixis (EXEL), BioInvent Tie Up for Immuno-Oncology Therapies

Exelixis (EXEL) looks to expand its biotherapeutics development pipeline by using BioInvent's proprietary immuno-oncology screening platform and antibody library.

BMY : 78.96 (+1.63%)
GERN : 1.3700 (+0.74%)
ALKS : 29.71 (+0.51%)
EXEL : 22.22 (+4.17%)
Bausch (BHC) Suspends IPO Plans for Solta Medical

Bausch (BHC) suspends its plans for the initial public offering of its Solta Medical business in light of the challenging market conditions and other factors.

GERN : 1.3700 (+0.74%)
ALKS : 29.71 (+0.51%)
BHC : 8.75 (+20.36%)
BOLT : 2.02 (-6.05%)
Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 70,000 shares of Geron common stock as an inducement to a newly hired employee...

GERN : 1.3700 (+0.74%)
Roche (RHHBY) Alzheimer's Disease Drug Data Disappoints

Roche's (RHHBY) study evaluating crenezumab in autosomal dominant Alzheimer's disease did not slow or prevent cognitive decline in people with a specific genetic mutation that causes its early onset.

BIIB : 211.93 (+0.26%)
RHHBY : 41.6400 (+4.07%)
GERN : 1.3700 (+0.74%)
ALKS : 29.71 (+0.51%)
Geron Corporation Announces Appointment of Faye Feller, M.D. to Chief Medical Officer and Transition of Aleksandra Rizo, M.D., Ph.D. to Senior Advisor Role

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Faye Feller, M.D., to Executive Vice President and Chief Medical Officer, effective...

GERN : 1.3700 (+0.74%)
Valneva (VALN) Down on its COVID-19 Vaccine Update in Europe

Valneva (VALN) slides on a proposed remediation plan update after receiving the European Commission's notice of intent to terminate the Advance Purchase Agreement for its COVID-19 vaccine.

PFE : 51.59 (+2.99%)
GERN : 1.3700 (+0.74%)
ALKS : 29.71 (+0.51%)
VALN : 27.27 (-13.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic...

See More

Key Turning Points

3rd Resistance Point 1.4733
2nd Resistance Point 1.4367
1st Resistance Point 1.4033
Last Price 1.3700
1st Support Level 1.3333
2nd Support Level 1.2967
3rd Support Level 1.2633

See More

52-Week High 1.7400
Fibonacci 61.8% 1.4535
Last Price 1.3700
Fibonacci 50% 1.3649
Fibonacci 38.2% 1.2764
52-Week Low 0.9899

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar